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Abstract: Brivaracetam is a new anticonvulsant compound, recently approved as an antiepileptic
drug. This drug substance presents a 4-substituted pyrrolidone structure: the (4R)-configuration of
the stereocenter present on the heterocyclic ring is the main target of the synthesis. The described
method allows to prepare the suitable optically pure 2-substituted primary alcohol by means
of a Pseudomonas fluorescens lipase-catalyzed transesterification. The obtained (2R)-alcohol was
easily transformed into the (3R)-3-propylbutyrolactone, an advanced intermediate of brivaracetam.
The described synthetic pathway is completed with the chromatographic methods and the NMR
analyses necessary to establish the chemical and the optical purity of the intermediates and of the
final lactone.
Keywords: biocatalysis; lipase; irreversible transesterification; (3R)-3-propylbutyrolactone
1. Introduction
Brivaracetam (1, chemical name (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide, brand
name Briviact®) is an antiepileptic drug approved in 2016 in Europe and USA [1–3]. This drug
substance exerts its pharmacological activity due to the high affinity for synaptic vesicle protein 2A
(SV2A), which is involved in the release of chemical messengers from nerve cells [3]. This helps
brivaracetam stabilize electrical activity in the brain and prevent seizures.
In the structure of brivaracetam (1) (Figure 1) two moieties can be recognized: a pyrrolidinone
ring and a butanamide; the two stereogenic centers at the 4-position of the heterocyclic ring and at the
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phosphoramide  anion  addition  to  an  α,β‐unsaturated  lactone  followed  by  hydrogenation  [5].  In 
1993, starting from the suitably functionalized ketene dithioacetal, the (R)‐isomer was obtained [6]. 
In 2016 two preparations of (R)‐lactone 4, utilized in the synthesis of brivaracetam, were described, 
starting  from  the  (R)‐epichlorohydrin  [7]  or  by  the  enzymatic  resolution  of  the 

























































































type  2, water,  30  °C,  42%  of  resolved  (R)‐2‐propylsuccinic  acid  4‐tert‐butyl  ester,  97.1%  ee;  (ii) 
ClCOOC2H5, (CH3CH2)3N, PhCH3, 0 °C; (iii) NaBH4, CH3OH, −20 °C; (iv) TFA, 25 °C, 91%, 95.9% ee.   
Fig re 1. Str ct res of brivaraceta a relate co o s.
Molecules 2018, 23, 2206; doi:10.3390/molecules23092206 www.mdpi.com/journal/molecules
Molecules 2018, 23, 2206 2 of 11
The presence of the 4-propyl group provides a tenfold higher affinity for SV2A than levetiracetam
(2), the brivaracetam analogue devoid of the 4-alkyl chain [4]. While (2S)-2-aminobutanamide
(3) is a commercially available compound, the relative difficulty to find suppliers of the optically
pure (4R)-propyl synthon stimulated us to develop a new synthetic approach to the preparation of
this chiral synthon. Among the possible precursors of the n-propyl containing moiety we selected
(3R)-3-propylbutyrolactone (4) and planned to obtain it through a biocatalytic approach. The choice
to work on this chiral synthon was also motivated by the fact that this compound is a known key
intermediate of the synthesis of brivaracetam.
The (S)-enantiomer of lactone 4 was already obtained in 2000 by Hanessian et al. by a
phosphoramide anion addition to an α,β-unsaturated lactone followed by hydrogenation [5]. In 1993,
starting from the suitably functionalized ketene dithioacetal, the (R)-isomer was obtained [6].
In 2016 two preparations of (R)-lactone 4, utilized in the synthesis of brivaracetam, were
described, starting from the (R)-epichlorohydrin [7] or by the enzymatic resolution of the
(R,S)-methyl-2-propylsuccinate-4-tert-butylester [8], with >99% (of brivaracetam, after crystallization)
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Scheme 1. Summary of the previously reported syntheses of optically active lactone 4. Reagents and
Conditions: (a) (i) O3, CH2Cl2, −78 ◦C, (CH3)2S, 95%; (ii) CH3 (Ph)3Br THF, nBuLi, −50 ◦C, 58%;
(iii) H2, Pd/C, CHCl3, 99%. (b) (i) nBuLi, THF; (ii) lC(O) 2Br; (iii) P(OC2H5)3, 50 ◦ ; (iv) NaH,
THF, 25 ◦C; (v) 1,3-dithiane-2-carbaldehyde; (vi) LDA, −78 ◦C; (vii) C3H7OTf; (viii) LiAlH4, THF, 0 ◦C,
95%; (ix) TsOH, CH2Cl2, 25 ◦C, 90%. (c) (i) CH3ONa, C2H5OH, 55%, 98% ee; (ii) CH3CH2MgBr, CuI,
64%; (iii) LiCl, DMSO/H2O, 140 ◦C, 18 h, 50% overall yields of ii+iii, ee not reported. (d) (i) Bacillus
subtilis type 2, water, 30 ◦C, 42% of resolved (R)-2-propylsuccinic acid 4-tert-butyl ester, 97.1% ee;
(ii) ClCOOC2H5, (CH3CH2)3N, PhCH3, 0 ◦C; (iii) NaBH4, CH3OH, −20 ◦C; (iv) TFA, 25 ◦C, 91%,
95.9% ee.
In 2018, (R)-lactone 4 was also prepared by crystallization of the amide obtained by the reaction of
(R,S)-lactone with (S)-1-benzylmethylamine [9]. A chemoenzymatic approach to the lactam precursor
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of 1, instead of the lactone, has recently been published: in this case the suitable γ-amino-β-chiral ester
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of  the unsaturated acetal 6 by means of baker’s yeast  (Saccharomyces cerevisiae). With  this aim we 
prepared  the  suitable  substrate  of  the microbiological  transformation,  compound  7,  following  a 
reported method [15]. 
The presence at 3‐position of a propyl chain instead of a methyl group required us to verify the 
stereochemical  outcome  of  the  bioreduction;  indeed,  the different  size  of  the  substituents  at  the 
stereogenic center, could, in principle, lead to a different chiral recognition by the microorganism. 
The hydroxyl ester obtained  from  the biotransformation was directly cyclized  [11]  to known 
lactone 4: the negative sign and the  low optical rotation value allowed us to assign the undesired 






Considering  the  very  good  results  observed  in  the  case  of  the  enzymatic  resolution  of 
(2R,S)‐2‐substituted  primary  alcohols  [16–18]  by  means  of  the  lipase‐catalyzed  irreversible 





Scheme 2. Synthesi of lactam, precursor of brivaracetam. Reagents and Conditions: (i) transaminase,
PLP, amine donor, 30 ◦C, 24 h; (ii) NaOH.
2. Results and Discussion
Our first att mpt to prepare the (R)-lactone 4 was carried out following the already described [11]
synthesis of (3S)-3-m thylbutyrolacto e (5), successfully applied and studied, in the past, also by
our research group [12–14] (Scheme 3). This method involves the stereoselective hydrogenation
of the unsaturated acetal 6 by means of baker’s yeast (Saccharomyces cerevisiae). With this aim we
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Scheme 3. Baker’s yeast-catalyzed biotransfor ations. Reagents and Conditions: (i) See reference [15];
(ii) CH(OCH2CH3)3, PTSA, C2H5OH, reflux, 48 h; (iii) Baker’s yeast, 30 ◦C, 48 h; (iv) CF3COOH, rt,
CH2Cl2, 10% from 7.
The pre ence a 3-position of a propyl chain instead of a m thyl group required us to verify
the stereoch m al outcome of th bioreduction; indeed, the different size of the substituents at the
stereogenic ce ter, c uld, in principle, lead to a different chiral recognition by the microorganism.
The hydroxyl ester obtained from the biotransformation was directly cyclized [11] to known
lactone 4: th negative sign and the low optical r tation value allowed us to assign th undesired
(S)-configuration and a low ee to the hydroxyl ester, by comparison with the re orted data [5]
(Scheme 3).
Considering the very good results observed in the case of the enzymatic resolution
of (2R,S)-2-substituted primary alcohols [16–18] by means of the lipase-catalyzed irreversible
transesterification [19,20] we decided to prepare a (2R,S)-2-propyl primary alcohol with the C-4
engaged in an aromatic ring, a suitable precursor of the carboxylic group. The choice was addressed
toward the 2-benzyl-1-pentanol (8), taking into account its similarity to the 2-benzyl-1-propanol (9),
the substrate of an already reported successful resolution by means of a lipase-catalyzed irreversible
transesterification [21].
The Perkin condensation between benzaldehyde and valeric anhydride afforded the
(E)-2-benzylidenpentanoate acid (10) that was transformed into the corresponding ethyl ester 11
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(53% yield from benzaldehyde) [22]. LiAlH4 in tetrahydrofuran, at reflux, afforded, by simultaneous
reduction of the ester and of the double bond, the desired alcohol 8 in 69% yield.
The first attempt of resolution of the alcohol 8 was carried out under the irreversible
transesterification conditions (vinyl acetate in dichloromethane) catalyzed by Pseudomonas fluorescens
lipase (PFL), that is, under the same conditions followed in the case of the alcohol 9. The observed
(by HPLC, Hitachi Ltd., Tokyo, Japan) conversion of the (R,S)-alcohol 8 into the corresponding acetate
12 was very low, with only 35% of the ester being formed after six days. The choice to change the
solvent of the enzymatic reaction from dichloromethane to toluene gave us satisfactory results: the
optically pure alcohol 8 was isolated, at 62% conversion, after 48 h, a time, nevertheless, higher than the
2 h required in the case of the alcohol 9 (Scheme 4). The (R)-configuration of the alcohol was assigned
by comparison with the reported data [23,24], and the optical purity was established by HPLC analysis
on chiral stationary phase (Phenomenex Lux 3 Cellulose-1, The (R)- and (S)-acetate 12, differently
from the (R)- and (S)-alcohol 8, were not resolved on the chiral HPLC column). The enantiomeric
ratio [25,26] (E = 20), calculated for this reaction, can be regarded as moderate to good for practical
purposes, according to a 2012 report of Faber and Kroutil [27].
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Candida  antarctica  lipase  (CAL  B,  Novozym®  435,  Novozymes,  Bagsværd,  Denmark)  was  not 
stereoselective while  either  Candida  cylindracea  lipase  (CCL)  and  porcine  pancreas  lipase  (PPL) 
showed low enantioselectivity (about 50% ee). 
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2  PFL  Dichloromethane  144  35  81 b, S  15 
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Scheme 4. Synthesis and enzymatic resolution of alcohol 8. Reagents and Conditions: (i) (C4H9CO)2O,
CH3COONa, py, 140 ◦C, 14 h; (ii) C2H5OH, H2SO4, reflux, 12 h, 53% from PhCHO; (iii) LiAlH4, THF,
reflux, 6 h, 69%; (iv) PFL, CH2=CH-OCOCH3, PhCH3, 31% of resolved (R)-8 at 62% conversion.
Other common commercially available lipases did not afford satisfactory results (see Table 1).
Indeed, the very fast transesterification of the (R,S)-alcohol 8 (61% conversion after 2 h) catalyzed
by Candida antarctica lipase (CAL B, Novozym® 435, Novozymes, Bagsværd, Denmark) was not
stereoselective while either Candida cylindracea lipase (CCL) and porcine pancreas lipase (PPL) showed
low enantioselectivity (about 50% ee).
Table 1. Enzymatic irreversible transesterification of compound 8.
Entry Enzyme Solvent Time (h) Conversion(%) a
Ee a, fi
8 E
1 PFL Toluene 48 62 99, R 20
2 PFL Dichloromethane 144 35 81 b, S 15
3 CCL Toluene 24 72 58, S 3
4 CAL B Toluene 2 61 5, R 1
5 PPL Toluene 192 71 53, S 2
a HPLC analysis on chiral st tion ry phase. b in this case the ee of the (S)-alcohol, obtained by hydrolysis (5%
NaOH in CH3OH) of the (S)-acetate 12, was evaluated.
Utilizing the optically pure (R)-alcohol 8, obtained by the PFL-catalyzed transesterification, we
proceeded with the synthesis of the (R)-lactone 4.
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The hydroxyl group was protected as acetate (86% yield) and the obtained ester (R)-12 was
submitted to the oxidative cleavage of the aromatic ring with ruthenium tetroxide, according to the
method described by Sharpless et al. [28].
The acetoxy acid 13, isolated in 84% yield, was converted into the desired (R)-lactone 4 by alkaline
hydrolysis of the acetate followed by a direct cyclization of the obtained hydroxyacid 14 by acidic
catalysis (1M hydrochloric acid). The lactone was recovered after purification in 77% yield. The ee
of the intermediate 13 was established by 1H-NMR analysis of the diastereomeric derivative 15,
prepared by reaction with the optically pure (R)-phenylethylamine: the signals due to the acetyl and
the CH2OCO- of the (3R)- and (3R,S)-derivatives 15 were compared confirming that the >98% ee of
(R)-8 was kept unaltered through the synthetic pathway. The same ee was maintained through the
synthesis on the final lactone (R)-4 as confirmed by chiral GC analysis (Lipodex E, Macherey-Nagel,
Düren, Germany): by comparison of the chromatograms of the (R,S)-lactone, obtained from (R,S)-8,
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Scheme 5. Transformation of (R)-alcohol 8 into (R)-lactone 4. Reagents and Conditions: (i) (CH3CO)2O,
py, rt, 2 h, 86%; (ii) RuCl3, NaIO4, CH3CN, ClCH2CH2Cl, H2O, 70 ◦C, 3 h, 84%; (iii) K2CO3, CH3OH,
reflux, 3 h; (iv) 1M HCl, rt, overnight, 77% from 13; (v) (COCl)2, (R)-(+)-α-phenylethylamine, CH2Cl2.
The optically pure (R)-lactone 4 has been already utilized as advanced intermediate of
brivaracetam: for example, the (R)-3-(chloromethyl)-hexanoyl chloride [7] or the ethyl ester of
(R)-3-(bromomethyl)-3-propylbutanoic acid [8], obtained by opening of the lactone ring, were reacted
with (S)-2-aminobutanamide to afford brivaracetam in 43% (>99% ee, after crystallization) and 23%
(95.9% ee from (R)-lactone 4 with 95.7% ee) overall yields, respectively, with suitable specifications for
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3. Materials and Methods
All reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Candida
antarctica lipase (CAL B, Novozym® 435, ≥10,000 U/g), Candida cylindracea lipase (CCL, 6.54 U/mg),
porcine pancreas lipase (PPL, 23.9 U/mg) and Pseudomonas fluorescens lipase (PFL, 40.2 U/mg) were
purchased from Sigma-Aldrich.
TLC analyses were performed on silica gel 60 F254 precoated plates with a fluorescent indicator
(Merck, Kenilworth, NJ, USA) with detection by spraying with 10% phosphomolybdic acid ethanol
solution and heating at 110 ◦C. Column chromatographies were performed on silica gel 60
(70–230 mesh) (Merck), 1:20 w/w substrate/silica gel.
Infrared spectra of neat samples were recorded on a Perkin Elmer instrument (Mod. Paragon
500 FT-IR Spectrometer, Perkin Elmer, Waltham, MA, USA). The values of optical rotations were
registered on a Perkin-Elmer (mod. 241) polarimeter in a 1 dm cell at 20 ◦C, setting the wavelength at
589 nm. Mass spectra were recorded on an Agilent 6330 Ion Trap instruments (ESI positive, Agilent
Technologies, Santa Clara, CA, USA) using the direct inlet probe technique; the samples were dissolved
in methanol at a final concentration of 0.006 mg/mL and injected at an infusion rate of 0.5 mL/h. Data
acquisition and analysis were accomplished with Bruker Daltonics Data Analysis 3.3 software (Bruker
Daltonics, Billerica, MA, USA). High resolution mass spectra (HRMS) were recorded on Impact HDTM
UHR-QqToF (Bruker Daltonics); acquisition parameters were set as following: Funnel1 RF 400 Vpp,
Funnel2 RF 400 Vpp, Hexapole RF 600 Vpp, transfer time 95 µs, pre-pulse storage 12 µs, 10–1000
m/z window. Calibration was performed online using ESI-L Low Concentration Tuning Mix (Agilent
Technologies); the samples were dissolved in methanol at a final concentration of 0.0006 mg/mL
and injected at an infusion rate of 0.5 mL/h. Data acquisition and analysis were accomplished with
Bruker Compass Data Analysis 4.1 software (Bruker Compass, Billerica, MA, USA). GC analyses were
performed with a Hewlett-Packard 5890 series II (Palo Alto, CA, USA). NMR spectra were recorded on
an AVANCE 500 spectrometer (Bruker, Billerica, MA, USA) equipped with a 5 mm broadband reverse
probe with field z-gradient operating at 500.13 and 125.76 MHz for 1H and 13C, respectively. NMR
spectra were recorded at 298 K in CDCl3 (isotopic enrichment 99.95%) solution. The data were collected
and processed by XWIN-NMR software (3.5, Bruker) running on a PC with Microsoft Windows 7
(Redmond, WA, USA). The samples (10 mg), were dissolved in the appropriate solvent (0.7 mL) in a
5 mm NMR tube. Acquisition parameters for 1D were as follows: 1H spectral width of 5000 Hz and
32 K data points providing a digital resolution of ca. 0.305 Hz per point, relaxation delay 10 s; 13C
spectral width of 29,412 Hz and 64 K data points providing a digital resolution of ca. 0.898 Hz per
point, relaxation delay 2 s. The experimental error in the measured 1H-1H coupling constants was±0.5
Hz. Chemical shifts (δ) of the 1H-NMR and 13C-NMR spectra are reported in ppm using the signal
for residual solvent protons resonance as internal standard (1H-NMR: CDCl3 7.26 ppm; 13C-NMR:
CDCl3 77.0 ppm (central line)). The splitting pattern abbreviations are as follows: s, singlet; d, doublet;
t, triplet; q, quartet; m, multiplet, and bs, broad signal. For two-dimensional experiments, Bruker
microprograms using gradient selection (gs) were applied. All two-dimensional spectra (COSY and
HSQC) were acquired with 2048 data points for t2 and 256 for t1 increments. The confirmations of the
structures of compounds 4, 8, 11, 12, and 13 were obtained by 500 MHz-NMR spectra, in particular
through proton and carbon 1D-NMR spectra, as well as by 2D-NMR homo-correlation (COSY) and
hetero-correlation (HSQC) experiments. The NMR, IR, MS and HRMS spectra and the HPLC, GC
chromatograms are available in the supplementary materials section.
3.1. Chemistry
3.1.1. (E)-Ethyl-2-benzylidenepentanoate (11)
Benzaldehyde (10 mL, 98.4 mmol), valeric anhydride (30.3 mL, 153.6 mmol), sodium acetate (4.5 g,
54.9 mmol) and pyridine (0.3 mL, 3.7 mmol) were heated at 140 ◦C, under stirring (14 h) monitoring
the reaction progress by TLC (heptane/acetone 7:3). After cooling at room temperature, the reaction
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mixture was poured in an aqueous solution of hydrochloric acid (300 mL, H2O/37% HClaq 8:2 v/v)
obtaining an emulsion. Water was removed (30 mmHg, 60 ◦C) to afford an oily residue. Water was
added (180 mL) and the obtained aqueous phase was extracted with dichloromethane (3 × 90 mL).
The collected organic phases were dried over sodium sulfate; after filtration, the solvent was removed
at reduced pressure, affording desired (E)-2-benzylidenepentanoic acid (10) (14.7 g) which was used
directly in the next step without any further purification. The 1H-NMR spectrum was in agreement
with the reported one [29].
To a solution of crude (E)-2-benzylidenepentanoic acid (10, 14.7 g) in dry ethanol (180 mL), 95–97%
sulfuric acid (5 mL, 93.8 mmol) was added dropwise under a nitrogen atmosphere. The solution
was kept at reflux, under stirring (12 h), monitoring the reaction progress by TLC (toluene/ethyl
acetate 9:1). The solution was cooled to 0–5 ◦C, the pH was adjusted to neutrality by the addition
of a 6% aqueous ammonium hydroxide solution and ethanol was removed under reduced pressure
(30 mmHg, 50 ◦C). The obtained aqueous phase was basified to pH 9 with 6% ammonium hydroxide
solution and extracted with dichloromethane (3 × 80 mL). The collected organic phases were dried
over sodium sulfate and after the usual work up a yellow oily residue (12.9 g) was obtained; the
residue was purified by silica gel column chromatography by elution with hexane/ethyl acetate (95:5)
giving pure (E)-ethyl 2-benzylidenepentanoate (11, 11.3 g, 51.8 mmol, 53% from benzaldehyde) as an
oil. Rf 0.83 (toluene/ethyl acetate 9:1). 1H-NMR [22]: 7.65 (s, 1H, CH=), 7.30–7.41 (m, 5H, Ar), 4.27 (q, J
= 7.1 Hz, 2H, CH2CH3), 2.49 (m, 2H, H-3), 1.53–1.62 (m, 2H, H-4), 1.35 (t, 3H, J = 7.1 Hz, CH3CH2),
0.96 (t, 3H, J = 7.3 Hz, H-5). 13C-NMR: 168.5 (C-1), 138.6 (PhCH=), 136.0 (Ar), 133.9 (C-2), 129.2, 128,4,
128.2 (Ar), 60.7 (OCH2CH3), 29.5 (C-3), 22.6 (C-4), 14.3 (CH3CH2), 14.2 (C-5). IR ν 2961.75, 2932.82,
2872.59, 1709.43, 1465.35, 1446.71, 1259.77, 1225.85, 1201.19, 1130.17, 767.24, 700.63 cm−1. MS (m/z)
241.5 [M + Na]+.
3.1.2. (R,S)-2-benzylpentan-1-ol (8)
To a suspension of lithium aluminum hydride (9.0 g, 237.2 mmol) in dry tetrahydrofuran
(150 mL), cooled at 0–5 ◦C, (E)-ethyl 2-benzylidenepentanoate (11) (8.5 g, 38.9 mmol) dissolved
in dry tetrahydrofuran (30 mL) was added dropwise, under inert atmosphere. The ice bath was then
removed, and the reaction mixture was kept at reflux (6 h); the reaction progress was monitored by
TLC (toluene/ethyl acetate 9:1) until the starting material disappearance. To the reaction mixture,
cooled at 0–5 ◦C, water (9 mL), 15% sodium hydroxide aqueous solution (9 mL), and water (27 mL)
were sequentially added. The white precipitate was removed by suction through a Celite pad.
The filtrate was evaporated at reduced pressure affording a light-yellow oily residue (6.9 g). The residue
was purified by silica gel column chromatography by elution with hexane/ethyl acetate (9:1) to
give pure (R,S)-2-benzylpentan-1-ol (8, 4.8 g, 26.9 mmol; 69%). Rf 0.40 (toluene/ethyl acetate 9:1).
1H-NMR [23,24]: 7.25–7.30 (m, 2H, Ar), 7.17–7.21 (m, 3H, Ar), 3.53 (d, J = 5.0 Hz, 2H, H-1), 2.64
(d, J = 7.3, 2H, PhCH2,), 1.81 (m, 1H, H-2), 1.24–1.45 (m, 5H, H-3, H-4 and exchangeable with D2O),
0.90 (t, J = 7.5 Hz, 3H, H-5). 13C-NMR [23,24]: 140.8, 129.2, 128.3, 125.8 (Ar), 64.9 (C-1), 42.4 (C-2),
37.7 (PhCH2), 33.1 (C-3), 20.1 (C-4), 14.3 (C-5). IR [23,24] ν 3343.95, 3084.85, 3062.51, 3026.81, 2957.07,
2928.70, 1603.22, 1495.59, 1465.77, 1454.37, 1040.02, 732.92, 699.94 cm−1. MS (m/z) 201.0 [M + Na]+.
3.1.3. (R)-2-benzylpentan-1-ol (8)
To a solution of (R,S)-2-benzylpentan-1-ol (8, 1.8 g, 10.2 mmol) in toluene (900 mL), vinyl acetate
(2.82 mL, 31 mmol) and PFL (180 mg, 40.2 U/mg) were sequentially added. The reaction mixture was
kept at 20 ◦C under vigorous stirring in a screw cap flask. The reaction progress and the ee of alcohol
8 were monitored by HPLC (column: Phenomenex Lux 3 Cellulose-1, 250 × 4.6 mm; UV detector
wavelength 220 nm, eluant: n-hexane/2-propanol 98:2; flow rate 0.5 mL × min−1). Rt (R)-alcohol
8 43.74 min; acetate 12 9.40 min (see also footnote in the text). The reaction was stopped when
alcohol 8 showed 99% ee (62% conversion); the enzyme was removed by filtration and the solvent
was evaporated at reduced pressure. The oily residue (1.8 g) was purified by silica gel column
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chromatography. By elution with hexane/ethyl acetate 95:5, acetate (S)-12 was recovered (1.28 g, 57%).
Elution with hexane/ethyl acetate 9:1 afforded alcohol (R)-8 (0.56 g, 31%). [α]20D + 9.4 (c 1, methanol).
For the (S)-enantiomer lit. [23] −9.9 (c 1.09, methanol).
3.1.4. (R)-2-benzylpentan-1-ol, Acetate (12)
To a solution of (R)-2-benzylpentan-1-ol (8, 0.440 g, 2.49 mmol) in dry pyridine (3.75 mL), acetic
anhydride (0.75 mL, 7.8 mmol) was added under inert atmosphere. The reaction mixture was kept at
room temperature under stirring for 2 h. The reaction progress was monitored by TLC (toluene/ethyl
acetate 9:1) until starting material disappearance. Water (6 mL) was added and the mixture was
extracted with dichloromethane (3 × 7.5 mL). The collected organic phases were washed with water
(3 × 6 mL), dried over sodium sulfate and filtered. Removal of the solvent at reduced pressure gave
title compound (R)-2-benzylpentyl acetate (12) as a light-yellow oil (0.470 mg, 2.13 mmol, 86%) which
was used in the next step without further purification. For analytical purposes a little amount (16 mg)
was purified by silica gel column chromatography. Elution with hexane/ethyl acetate 95:5 afforded
pure acetate-12. Rf 0.76 (toluene/ethyl acetate 9:1). 1H-NMR: 7.25–7.31 (m, 2H, Ar), 7.13–7.21 (m, 3H,
Ar), 3.95 (d, J = 5.3 Hz, 2H, H-1), 2.63 (d, J = 7.0 Hz, 2H, PhCH2), 2.04 (s, 3H, CH3), 1.98 (m, 1H, H-2),
1.26–1.40 (m, 4H, H-3 and H-4), 0.93 (t, J = 7.0 Hz, 3H, H-5). 13C-NMR: 171.2 (CO), 140.2, 129.1, 128.3,
125.9 (Ar), 66.5 (C-1), 39.1 (C-2), 37.9 (PhCH2), 33.3 (C-3), 20.9 (CH3CO), 19.9 (C-4), 14.2 (C-5). IR ν
3085.86, 3063.45, 3027.82, 2958.22, 2872.73, 1738.63, 1603.76, 1495.90, 1466.58, 1455.21, 1385.12, 1365.87,
1239.08, 1039.32, 734.54, 700.64 cm−1. [α]20D − 14.1 (c 1, chloroform). MS (m/z) 243.0 [M + Na]+. HRMS
(ESI) m/z: Calcd. for C14H20NaO2 [M + Na]+ 243.1361. Found 243.1354.
3.1.5. (R)-3-(acetoxymethyl)hexanoic Acid (13)
To a mixture of (R)-2-benzylpentyl acetate (12, 0.42 g, 1.92 mmol), acetonitrile (7.5 mL),
1,2-dichloroethane (7.5 mL) and water (19 mL), ruthenium (III) chloride (77 mg, 0.36 mmol) and
sodium periodate (8.7 g, 40.8 mmol) were sequentially added. The reaction mixture was kept at 70
◦C under stirring (3 h), monitoring the reaction progress by TLC (hexane/acetone 8:2). The reaction
mixture was cooled at room temperature and filtered through a Celite pad, washing the pad with
dichloromethane (15 mL). The organic phase was separated, and the aqueous phase was extracted with
dichloromethane (2 × 15 mL). The collected organic phases were dried over sodium sulfate, filtered
and concentrated under reduced pressure to afford a dark violet oil. The oil was taken up in diethyl
ether and passed through a pad of Celite and Florisil (1:1). The solvent was removed under reduced
pressure affording (R)-3-(acetoxymethyl)hexanoic acid 13 (300 mg, 1.59 mmol, 84%) which was used in
the next step without further purification. For analytical purposes a sample (40 mg) was purified by
silica gel column chromatography. Elution with hexane/acetone 85:15 afforded pure title compound
13. Rf 0.39 (hexane/acetone 8:2). 1H-NMR: 4.12 (dd, J = 4.8 and 10.8 Hz, 1H, CHa–OCO), 3.95 (dd,
J = 6.8 and 10.8 Hz, CHb–OCO), 2.38 (m, 2H, H-2), 2.23 (m, 1H, H-3), 2.05 (s, 3H, CH3CO), 1.30–1.40
(m, 4H, H-4 and H-5), 0.91 (t, J = 6.9 Hz, 3H, H-6). 13C-NMR: 178.8 (C-1), 171.1 (CH3CO), 66.5 (CH2O),
36.5 (C-2), 34.3 (C-3), 33.3 (C-4), 20.8 (CH3CO), 19.8 (C-5), 14.1 (C-6). IR ν 3450.00, 3105.26, 2960.66,
2874.87, 2673.68, 1741.03, 1708.51, 1242.13, 1041.89 cm−1. [α]20D + 3.5 (c 1, chloroform). MS (m/z) 210.9
[M + Na]+. HRMS (ESI) m/z: Calcd. for C9H15Na2O4 [M-H + 2Na]+ 233.0766. Found 233.0761.
3.1.6. (R)-4-propyldihydrofuran-2(3H)-one (4)
To a solution of (R)-3-(acetoxymethyl)hexanoic acid (13, 145 mg, 0.78 mmol) in methanol (13
mL) potassium carbonate (0.600 g, 4.35 mmol) was added. The reaction mixture was kept at reflux
under stirring (3 h), monitoring the reaction progress by TLC (hexane/acetone 8:2) until starting
material disappearance. The solvent was removed at reduced pressure (30 mmHg, 40 ◦C) and the
residue was taken up with water (6 mL). The solution of hydroxyacid 14 was cooled at 0–5 ◦C and
pH was adjusted to 3 by addition of a 1M aqueous hydrogen chloride solution. The solution was
stirred at room temperature overnight. The reaction progress was monitored by TLC (hexane/acetone
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8:2). The reaction mixture was extracted with dichloromethane (3 × 15 mL). The collected organic
phases were dried over sodium sulfate; after filtration, the solvent was removed at reduced pressure,
to afford crude (R)-4-propyldihydrofuran-2(3H)-one (4, 102 mg) which was purified by silica gel
column chromatography. Elution with hexane/acetone 9:1 afforded pure (R)-4 (75 mg, 0.60 mmol,
77%). Rf 0.55 (hexane/acetone 8:2). GC (column: Macherey-Nagel Lipodex E, 25m × 250 µm; FID
detector at 220 ◦C, carrier gas helium; injector 200 ◦C; column inlet pressure 60 kPa; split ratio 1:100
gradient: 68 min run (70 ◦C/1 min, 70 to 122 ◦C/52 min, 122 ◦C/15 min). Rt (R)-lactone 4 57.75 min.
The (S)-lactone peak (Rt 58.57 min) is not detectable. 1H-NMR [5,6]: 4.41 (dd, J = 7.3 and 9.2 Hz, Ha-5),
3.92 (dd, J = 7.1 and 9.3 Hz, Hb-5), 2.50–2.65 (m, 2H, Ha-3 and H-4), 2.17 (dd, J= 7.8 and 16.1 Hz, Hb-3),
1.42–1.49 (m, 2H, CH2–CH), 1.29–1.39 (m, 2H, CH2CH3), 0.93 (t, J = 7.3 Hz, 3H, CH3). 13C-NMR [5,6]:
177.2 (C-2), 73.4 (C-5), 35.5 (C-4), 35.3 (CH2–CH), 34.5 (C-3), 20.6 (CH2CH3), 13.9 (CH3). IR [6] ν
3530.81, 2960.55, 2930.02, 2873.93, 1774.46, 1466.22, 1420.21, 1379.61, 1170.61, 1015.84 cm−1. [α]20D + 8.4
(c 1, ethanol). For for (S)-enantiomer lit. [5] −5.6 (c 0.9, ethanol), for (R)-enantiomer lit. [6] +6.7 (c 3.9,
ethanol). MS (m/z) 150.9 [M + Na]+.
3.1.7. Diastereomeric Derivative 15 of (R)-3-(acetoxymethyl)hexanoic Acid (13)
A solution of the acetoxy acid 13 (18.7 mg, 0.1 mmol) in anhydrous dichloromethane (0.5 mL) was
treated with oxalyl chloride (11 µL, 0.13 mmol), in the presence of dimethylformamide (20 µL), at 0 ◦C.
After 1 h, the solution was concentrated under nitrogen flow and (R)-(+)-methylbenzylamine (52 µL,
0.4 mmol) was added. After 30’ ethyl acetate (2 mL) was added. The obtained solution was sequentially
washed with 6M hydrochloric acid (3 × 1 mL), 3% aqueous ammonium hydroxide solution (3 × 1 mL),
water (2 mL); finally, solvent was removed at reduced pressure.
For the 500 MHz 1H-NMR analysis, the resonances of the (R)- and (S)-CH2OCOCH3 or the CH3CO
group were first established from spectra of the derivative of (R,S)-13, then they were compared with
that of the derivative of (R)-3-(acetoxymethyl)hexanoic acid 13. In the spectrum of derivative of
(R,S)-13 two singlets at 1.94 and 2.05 ppm were present, due to the CH3CO group protons. In the
spectrum of derivative of (R)-13 only the singlet at 1.94 ppm was present. The signal due to the proton
Ha of CH2OCO group was a double doublet centered at 4.01 ppm for the derivative of (R)-13, while
two dd (centered at 4.05 and 4.01 ppm) were present in the spectrum of amide of (R,S)-13.
4. Conclusions
The optically pure key intermediate (R)-lactone 4 of brivaracetam (1), an orally or intravenously
administered antiepileptic drug, was prepared by means of an enzymatic resolution, under the
classical irreversible transesterifications conditions, of a suitable alcohol easily prepared in 36%
overall yields starting from benzaldehyde. The transformation of the (R)-alcohol 8 into the final
(R)-lactone 4 was efficiently accomplished in few steps, keeping unaltered the ee of the starting
material. The whole synthesis involves simple steps and it can also be employed for preparative
purposes; ruthenium tetroxide is used in catalytic amount due to its continue recycling by sodium
periodate. Only few chromatographic purifications are required, appreciable amounts of by-products
being formed only during the Perkin condensation. The relatively low yield (53%) of this step,
however, can be considered acceptable taking into consideration the cheap starting materials utilized,
benzaldehyde and valeric anhydride.
The PFL-catalyzed acetylation applied to the resolution of 2-substituted primary alcohols,
under the irreversible transesterification conditions, once again, gave excellent results, showing the
enantiopreference in agreement with the Kazlauskas rule [30]: the modified reaction conditions (i.e.,
different solvent, increased enzymatic units/substrate mmoles ratio, and longer reaction time) respect
to the resolution of the very similar alcohol 9 are, probably, due to a different preparation of commercial
PFL and to the larger hindrance of the 2-substituent of the enzymatic substrate. The optimization
of the analytical chromatographic methods (GC and HPLC) on chiral stationary phases, aimed to
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the evaluation of the ee of the chiral compounds, and the careful NMR analyses provide a useful
complement of the synthesis.
Supplementary Materials: The NMR, IR, MS and HRMS spectra and the HPLC, GC chromatograms are
available online.
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